Clinicopathologic characteristics of patients with CNS or systemic (non-CNS) recurrence
| . | All (n = 26) . | CNS recurrence (n = 13) . | Systemic recurrence (n = 13) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 60 (32-84) | 61 (43-71) | 57 (32-84) | .74 |
| Sex, n (%) | .69 | |||
| M | 16 (62) | 9 (69) | 7 (54) | |
| F | 10 (38) | 4 (31) | 6 (46) | |
| HIV+, n (%) | 2 (8) | 1 (8) | 1 (8) | .99 |
| Stage 3 or 4, n (%) | 21 (81) | 10 (77) | 11 (85) | .99 |
| LDH, median (IQR), U/L | 306 (172-537) | 375 (170-668) | 284 (198-315) | .49 |
| Extranodal involvement, n (%) | 19 (73) | 10 (77) | 9 (69) | .99 |
| Testis | 4 | 3 | 1 | |
| Bone marrow | 5 | 2 | 3 | |
| Kidney | 2 | 1 | 1 | |
| Bone | 3 | 1 | 2 | |
| Gastrointestinal | 3 | 1 | 2 | |
| Uterus | 1 | 1 | 0 | |
| Skin (leg-type DLBCL) | 0 | 1 | 0 | |
| Dual expresser, n (%)* | 10 (43) | 6 (60) | 4 (31) | .22 |
| Double-hit lymphoma, n (%) | 4 (15) | 4 (31) | 0 (0) | .10 |
| Complex karyotype, n (%) | 5 (19) | 3 (23) | 3 (23) | .99 |
| COO by Hans algorithm | .70 | |||
| GCB, n (%) | 14 (54) | 6 (46) | 8 (62) | |
| non-GCB, n (%) | 12 (46) | 7 (54) | 5 (38) | |
| CNS-IPI | .19 | |||
| Low, n (%) | 4 (15) | 3 (23) | 1 (8) | |
| Intermediate, n (%) | 20 (77) | 8 (62) | 12 (92) | |
| High, n (%) | 2 (8) | 2 (15) | 0 (0) | |
| First-line regimen, n (%) | .99 | |||
| R-CHOP | 16 (62) | 8 (62) | 8 (62) | |
| DA-EPOCH-R | 9 (35) | 5 (38) | 4 (31) | |
| Other | 1 (4) | 0 (0) | 1 (8) | |
| CNS prophylaxis, n (%) | 10 (38) | 7 (54) | 3 (23) | .23 |
| Intrathecal | 9 (35) | 6 (46) | 3 (23) | |
| Systemic methotrexate | 3 (12) | 3 (23) | 0 (0) | .22 |
| . | All (n = 26) . | CNS recurrence (n = 13) . | Systemic recurrence (n = 13) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 60 (32-84) | 61 (43-71) | 57 (32-84) | .74 |
| Sex, n (%) | .69 | |||
| M | 16 (62) | 9 (69) | 7 (54) | |
| F | 10 (38) | 4 (31) | 6 (46) | |
| HIV+, n (%) | 2 (8) | 1 (8) | 1 (8) | .99 |
| Stage 3 or 4, n (%) | 21 (81) | 10 (77) | 11 (85) | .99 |
| LDH, median (IQR), U/L | 306 (172-537) | 375 (170-668) | 284 (198-315) | .49 |
| Extranodal involvement, n (%) | 19 (73) | 10 (77) | 9 (69) | .99 |
| Testis | 4 | 3 | 1 | |
| Bone marrow | 5 | 2 | 3 | |
| Kidney | 2 | 1 | 1 | |
| Bone | 3 | 1 | 2 | |
| Gastrointestinal | 3 | 1 | 2 | |
| Uterus | 1 | 1 | 0 | |
| Skin (leg-type DLBCL) | 0 | 1 | 0 | |
| Dual expresser, n (%)* | 10 (43) | 6 (60) | 4 (31) | .22 |
| Double-hit lymphoma, n (%) | 4 (15) | 4 (31) | 0 (0) | .10 |
| Complex karyotype, n (%) | 5 (19) | 3 (23) | 3 (23) | .99 |
| COO by Hans algorithm | .70 | |||
| GCB, n (%) | 14 (54) | 6 (46) | 8 (62) | |
| non-GCB, n (%) | 12 (46) | 7 (54) | 5 (38) | |
| CNS-IPI | .19 | |||
| Low, n (%) | 4 (15) | 3 (23) | 1 (8) | |
| Intermediate, n (%) | 20 (77) | 8 (62) | 12 (92) | |
| High, n (%) | 2 (8) | 2 (15) | 0 (0) | |
| First-line regimen, n (%) | .99 | |||
| R-CHOP | 16 (62) | 8 (62) | 8 (62) | |
| DA-EPOCH-R | 9 (35) | 5 (38) | 4 (31) | |
| Other | 1 (4) | 0 (0) | 1 (8) | |
| CNS prophylaxis, n (%) | 10 (38) | 7 (54) | 3 (23) | .23 |
| Intrathecal | 9 (35) | 6 (46) | 3 (23) | |
| Systemic methotrexate | 3 (12) | 3 (23) | 0 (0) | .22 |
Excluding 3 cases with missing data.
DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; F, female; GCB, germinal center B cell; IQR, interquartile range; LDH, lactate dehydrogenase; M, male; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.